Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allakos Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALLK
Nasdaq
2834
https://www.allakos.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allakos Inc
With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners
- May 3rd, 2024 10:59 am
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
- Apr 4th, 2024 12:36 pm
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
- Mar 16th, 2024 9:31 am
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 14th, 2024 8:02 pm
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Feb 26th, 2024 12:02 pm
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Feb 12th, 2024 12:02 pm
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
- Jan 18th, 2024 3:21 pm
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
- Jan 18th, 2024 2:35 pm
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
- Jan 17th, 2024 5:10 pm
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
- Jan 16th, 2024 2:40 pm
UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies
- Jan 16th, 2024 12:27 pm
Allakos Announces a Restructuring to Focus on Development of AK006
- Jan 16th, 2024 12:02 pm
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Jan 16th, 2024 12:00 pm
Allakos to lay off half of staff, scrap drug after study setback
- Jan 16th, 2024 10:09 am
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
- Jan 9th, 2024 12:34 pm
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023
- Nov 13th, 2023 10:01 pm
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Nov 13th, 2023 9:02 pm
Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners
- Nov 6th, 2023 10:17 am
Why Shares of Allakos Are Up Wednesday
- Sep 27th, 2023 4:10 pm
Allakos Appoints Neil Graham to its Board of Directors
- Aug 30th, 2023 8:05 pm
Scroll